Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 193.7 billion at a CAGR of 23% between 2024 and 2029.

The market is experiencing robust growth, driven by several key factors. Increased funding for vaccine development and the launch of new vaccines are major catalysts, particularly for chronic infections where novel solutions are in high demand. Another significant trend is the increasing use of adjuvants in vaccines, which enhance their efficacy and broaden their application. These developments reflect the market's response to the growing demand for advanced, innovative solutions. Moreover, advancements in medical technology and changing consumer preferences are shaping the market landscape. There is a transition towards more efficient systems, better accessibility, and higher industry standards. 
The vaccine market's future growth is underpinned by these drivers, which continue to influence its direction. As the market evolves, efforts to meet the growing demand for advanced solutions are expanding its scope, ensuring long-term growth. The industry's focus on delivering innovative, effective vaccines is a testament to its commitment to addressing global health challenges posed by infectious diseases and improving overall public health.

What will be the size of the market during the forecast period?

Request Free Sample

Vaccines Market Segmentation

The vaccines market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.TypeHuman vaccineAnimal vaccineEnd-userHospitalsClinicsRoute of AdministrationOralParenteralNasalOralParenteralNasalAge GroupPediatricAdultPediatricAdultTechnologyConjugateRecombinantLive AttenuatedOthersDiseaseViralBacterialParasiticOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyRussiaUKAsiaRest of World (ROW)

Which is the largest segment driving market growth?

The human vaccine segment is estimated to witness significant growth during the forecast period. The human market encompasses a vast array of products designed to prevent infectious diseases and foster global health. These vaccines function by stimulating the immune system to respond to specific pathogens, thereby conferring immunity against various diseases. Human vaccines can be classified into several types based on their composition, mechanism of action, and target population. One significant category is inactivated or killed vaccines, which utilize heat, chemicals, or radiation to render pathogens non-infectious. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These vaccines offer increased safety for individuals with compromised immune systems but may necessitate multiple doses to achieve adequate immunity.

Other types of human vaccines include therapeutic vaccines, conjugate vaccines, recombinant vaccines, live attenuated vaccines, toxoid vaccines, and subunit vaccines. These vaccines play a pivotal role in protecting billions of people from diseases and promoting overall health.

Get a glance at the market share of various regions. Download the PDF Sample

The Human vaccine segment was valued at USD 57.40 billion in 2019 and showed a gradual increase during the forecast period.

Advancements in vaccine development are being driven by cutting-edge technologies such as nanoparticle vaccines and mRNA platforms, which enable highly targeted immune responses. The incorporation of adjuvant systems and immune modulators enhances vaccine efficacy, while viral vectors, DNA vaccines, and synthetic peptides offer diverse strategies for antigen design. Needle-free delivery methods, such as microneedle patches, are improving patient comfort and access, with the potential to revolutionize immunization tech. Innovations in cold chain technology and smart packaging, paired with digital tracking and blockchain records, ensure the safe transport and storage of vaccines. AI diagnostics and machine learning-driven predictive models are accelerating the development and evaluation of vaccines, while bioengineering tools enable precision dosing and rapid production. In addition, recombinant proteins, conjugate systems, and live attenuated or toxoid formulas continue to offer robust options for therapeutic vaccines. The use of sustainable materials and eco-friendly vials further reflects the growing focus on environmentally conscious practices in vaccine production. Data analytics are playing a pivotal role in optimizing vaccine delivery and monitoring outcomes.

Which region is leading the market?

North America is estimated to contribute 39% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regio

The size and share of the market is categorized based on Application (Residential property, Commercial property, Industrial property, Government properties) and Product (Real estate management, Facility management, Property maintenance, Leasing services) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The size of the Human Vaccine Market was valued at USD 50.74 billion in 2024 and is projected to reach USD 95.71 billion by 2033, with an expected CAGR of 9.49% during the forecast period. This expansion is fueled by several key factors. The increasing prevalence of infectious diseases, coupled with rising public awareness of the importance of vaccination, forms a strong foundation for market growth. Government initiatives promoting vaccination programs, particularly in developing nations, significantly contribute to market expansion. Furthermore, advancements in vaccine technology, such as mRNA vaccines and novel delivery systems, are driving innovation and broadening the market's potential. The development of multivalent vaccines, offering protection against multiple diseases simultaneously, is also contributing to the market's expansion. Finally, increased research and development efforts by pharmaceutical companies, coupled with strategic collaborations and mergers and acquisitions, are accelerating the introduction of new and improved vaccines, further fueling market growth.

Vaccines are classified based on technology, route of administration, type, disease indication, end-user, and composition. Each segment caters to specific market needs and preferences. Recent developments include: April 2022:Dante Labs reported that the company was selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines. Dante and the ADSCC will partner on the launch of an R&D program focusing on personalized treatments for oncology patients and, eventually, the development of cancer vaccines.. Key drivers for this market are: The growing emphasis on personalized experiences, customer journey mapping, and the ability to optimize app performance in real-time are key drivers of market growth. Potential restraints include: complexity in data integration. Notable trends are: Strong Supply Backed Up by Robust R&D is driving the market growth.

This statistic describes the size of the total global human vaccine market from 2014 to 2024. It is projected that the global vaccine market will generate nearly 62 billion U.S. dollars by 2024. That would be more than double the size in 2016.

Snapshot img

Human Combination Vaccines Market Size 2024-2028

The human combination vaccines market size is forecast to increase by USD 7.03 billion at a CAGR of 8.69% between 2023 and 2028.

The market is experiencing significant growth due to several key trends and challenges. One of the primary drivers is the increasing antiviral drug resistance, which has led to a greater emphasis on preventive measures through vaccines. Additionally, the threat from bioterrorism has heightened the need for effective combination vaccines to protect against multiple diseases simultaneously. Vaccine distribution challenges, such as vaccine refrigeration and packaging, are significant considerations in the market. Furthermore, the consolidation of different immunization schedules is streamlining vaccine administration and increasing convenience for healthcare providers and patients. These trends are shaping the market and are expected to continue driving growth In the coming years.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses the production and distribution of vaccines that protect against multiple diseases with a single administration. This market is driven by the newborn population growth and the ongoing need for pediatric immunization. Inactivated virus vaccines and live attenuated vaccines are the primary types of combination vaccines, each offering unique advantages in terms of vaccine safety, effectiveness, and ease of administration. Immunization coverage rates vary globally, with ongoing efforts to increase vaccination adoption and combat vaccine resistance. The threat of bioterrorism and emerging infectious diseases further underscores the importance of vaccine development and immunization campaigns.
The global vaccine market is experiencing steady growth, fueled by advancements in vaccine technology, including pathogen inactivation and multi-dose vaccine administration. Vaccine compliance remains a crucial factor, with ongoing initiatives to improve vaccine safety, effectiveness, and vaccine compliance. The vaccine supply chain is a critical component of the market, with ongoing efforts to ensure a reliable and efficient distribution network. Disease prevention remains the primary focus of the market, with ongoing research and development aimed at addressing vaccine resistance and emerging diseases. The market is expected to continue growing, driven by the need to protect global populations from infectious diseases and ensure public health and safety.

How is this Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Inactivated vaccine
  Live attenuated vaccine


Channel

  Hospitals
  Retailers
  Online


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    Japan


  Rest of World (ROW)

By Type Insights

The inactivated vaccine segment is estimated to witness significant growth during the forecast period.The inactivated segment dominates The market due to its superior tolerability and fewer complications when multiple antigens are used. Inactivated human combination vaccines, such as those for Chickenpox, DTaP, IPV, Pediarix, Pentacel, and Tetraxim, are preferred due to their ability to provide comprehensive protection against various diseases. However, producing these vaccines poses challenges due to potential antigen incompatibilities and interactions among ingredients. Inactivated vaccines are developed using pathogen particles that have been destroyed or killed, ensuring a strong immune response against the targeted organisms. Medical practitioners prioritize these vaccines due to their effectiveness in preventing diseases, including Diphtheria, Tetanus, Acellular pertussis, Polio, and Hib.

Get a glance at the market report of share of various segments Request Free Sample

The inactivated vaccine segment was valued at USD 8.8 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American market holds the largest share in 2023, driven by stringent regulatory policies mandating infant vaccination. Despite a slower growth rate due to decreasing infectious disease prevalence, the market expansion is fueled by ongoing initiatives to promote vaccine usage. In other regions, the market is driven by the rising incidence of di

The report covers Human Papillomavirus Vaccine Market and the market is segmented by Type (Bivalent, Quadrivalent, Nona valent), Indication (Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer, Genital Warts, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

The global vaccine market size reached USD 59.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 136.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.12% during 2025-2033. The implementation of stringent regulations promoting the adoption of vaccination among individuals, several advances in biotechnology and vaccine development techniques, and the growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.

The demand for human vaccines in China has been growing along with a rising public healthcare expenditure. By 2030, China's vaccination market size was projected to reach 132 billion yuan in terms of sales revenue. Currently, domestic vaccines have been dominating the market supply in China.

The size and share of the market is categorized based on Application (Hospital, Scientific Research, Others) and Product (Inactivated Vaccine, Attenuated Vaccine, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

Global Prophylactic Human Vaccine market size 2025 was XX Million. Prophylactic Human Vaccine Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

The market size of the Dna Vaccines Market is categorized based on Application (Human, Animal) and Product (Recombinant Protein Vaccine, Gene-Based Vaccine) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This report provides insights into the market size and forecasts the value of the market, expressed in USD million, across these defined segments.

Explore the article discussing the projected growth of the vaccine market for human medicine, with an expected increase in consumption over the next decade. Forecasted to see significant expansion in market volume and value by 2035.

Market Overview:

The United States vaccines market size is projected to exhibit a growth rate (CAGR) of 5.91% during 2024-2032. The regulatory support and approval processes, the emerging infectious diseases, the rise of telehealth and remote healthcare services, the favorable healthcare policies, and the international collaborations and partnerships are some of the factors propelling the market.

Vaccines are biological substances designed to stimulate the immune system to recognize and fight specific pathogens, such as viruses or bacteria. They play a crucial role in preventing infectious diseases and promoting public health. Vaccines are typically composed of weakened or inactivated forms of the targeted microorganism or specific components, such as proteins or genetic material. When administered, vaccines prompt the immune system to produce an immune response, including the production of antibodies and the development of immune memory. This immune memory allows the body to recognize and rapidly respond to the actual pathogen if encountered in the future, providing protection against infection and often preventing the onset of diseases. Vaccination programs have been instrumental in controlling and eradicating infectious diseases globally. Common vaccines include those for measles, mumps, rubella, polio, influenza, hepatitis, and more. In addition to individual protection, vaccines contribute to herd immunity, reducing the overall spread of infectious agents within communities. Continuous research and advancements in vaccine technology, such as mRNA vaccines, have expanded the scope and efficacy of vaccination efforts. Vaccines have been pivotal in controlling pandemics, as evidenced by their role in combating diseases like smallpox and, more recently, in the global response to the COVID-19 pandemic. They represent a powerful tool in public health, preventing illness, reducing the burden on healthcare systems, and saving countless lives by effectively bolstering the body's immune defenses against a wide array of infectious agents.

United States Vaccines Market Trends:

The market in the United States is majorly driven by the advancements in vaccine development. In line with this, the COVID-19 pandemic has accelerated vaccine research, production, and distribution efforts. The urgency to address the global health crisis has led to increased investments, collaborations, and government support for vaccine development, contributing significantly to market growth. Furthermore, the rising awareness of the importance of vaccination in preventing infectious diseases has driven demand. Routine vaccinations for diseases like influenza, measles, mumps, rubella, and hepatitis have gained prominence as individuals and healthcare providers recognize the value of immunization in maintaining public health. Government initiatives and public health programs play a pivotal role in driving the vaccine market. Programs such as the Vaccines for Children (VFC) program, which provides vaccines to eligible children, and the Adult Immunization Initiative contribute to increased vaccine accessibility and utilization. Additionally, the emergence of innovative vaccine technologies has expanded the market. mRNA vaccine platforms, as demonstrated by the success of COVID-19 vaccines, showcase the potential for rapid development and effectiveness against a variety of pathogens. This has spurred interest and investment in novel vaccine approaches, driving market growth. The aging population in the United States is a significant factor influencing the vaccine market. As individuals age, there is a higher susceptibility to certain diseases, necessitating vaccinations to prevent complications. This demographic shift contributes to the demand for vaccines targeting conditions prevalent in older adults, such as shingles and pneumococcal diseases. Pharmaceutical companies and biotech firms are increasingly focusing on vaccine research and development. Partnerships between industry players and research institutions, along with advancements in vaccine manufacturing technologies, drive innovation and contribute to the growth of the vaccine market. Besides, the growing importance of travel vaccines, as people increasingly engage in international travel, adds to market expansion. Vaccines for diseases prevalent in different regions become essential for travelers, promoting a global market for travel-related immunizations.

United States Vaccines Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.

Technology Insights:

https://www.imarcgroup.com/CKEditor/4df2be45-fb2f-4a09-890a-76b18e7708deother-regions1.webp" style="height:450px; width:800px" />

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others
  

The report has provided a detailed breakup and analysis of the market based on the technology. This includes conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and others.

Patient Type Insights:

• Pediatric
• Adult
  

A detailed breakup and analysis of the market based on patient type have also been provided in the report. This includes pediatric and adult.

Indication Insights:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others
    

The report has provided a detailed breakup and analysis of the market based on the indication. This includes bacterial diseases (meningococcal disease, pneumococcal disease, diphtheria/tetanus/pertussis (DPT), tuberculosis, haemophilus influenzae (HIB), typhoid, and others) and viral diseases (hepatitis, influenza, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue, and others).

Route of Administration Insights:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others
  

A detailed breakup and analysis of the market based on route of administrations have also been provided in the report. This includes intramuscular and subcutaneous administration, oral administration, and others.

Product Type Insights:

• Multivalent Vaccine
• Monovalent Vaccine
  

<p

The North America Human Vaccines market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor dynamics, helping companies align their strategies with the current market landscape and future trends.

This statistic describes the total size of the human vaccine market in the United States from 2014 to 2024. It is projected that the total human vaccine market in the U.S. will generate nearly 26 billion U.S. dollars by 2024.

Get the sample copy of Human Vaccines Administered Orally Market Report 2025 (Global Edition) which includes data such as Market Size, Share, Growth, CAGR, Forecast, Revenue, list of Human Vaccines Administered Orally Companies (Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, Tiantan Biological, EuBiologics, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals), Market Segmented by Type (Rotavirus Vaccine, Cholera Vaccine, Oral Polio Vaccine), by Application (Public, Private)

The global market for vaccines in human medicine is expected to see steady growth over the next six years, driven by increasing demand. Market performance is forecast to expand with a CAGR of +0.5%, reaching 104K tons in volume and $111.3B in value by 2030.

This statistic describes the size of the human vaccine market in the United States from 2014 to 2024, comparing the adult vaccine vs. the pediatric vaccine market. It is projected that the adult vaccine market in the U.S. will generate nearly 12 billion U.S. dollars by 2024.

Global Adult Vaccines Market size was $20 billion in 2022 and is slated to hit $30 billion by the end of 2030 with a CAGR of nearly 6.03%.